Samsung Biologics Co.,Ltd.
207940.KS
Updated: 24/09/2026, 05:14:34
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
No summaries found.
- Share price
- ₩1,366,000
- Market cap
- ₩63.23T
- Exchange
- KSC
- Currency
- KRW
- CEO
- John Chongbo Rim
- Employees
- 5,455
- IPO date
- 11/11/2016
- Beta
- 0.198
- Last dividend
- ₩0
- Day range
- ₩1,360,000 – ₩1,394,000
- 52-week range
- ₩1,228,000 – ₩1,987,000
- 1-day performance
- -1.80%
- 1-year performance
- 11.24%
- Current drawdown (1Y)
- -31.25%
- CIK
- N/A
- CUSIP
- N/A
- ISIN
- KR7207940008
- Created
- 07/09/2026, 05:16:37
- Last update
- 24/09/2026, 05:14:34
Track Samsung Biologics Co.,Ltd. with an AI analyst
See which prediction-market events move 207940.KS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.